Blade Finalizes Sale of Passenger Division and Announces Name Change to Strata Critical Medical, Commences Trading as SRTA

Written by Emily J. Thompson, Senior Investment Analyst

JOBY-2.58%

Source: Globenewswire

Updated: Aug 29 2025

0mins

Source: Globenewswire

Company Transition and Divestiture

Divestiture Details: Strata Critical Medical, Inc. has successfully completed the divestiture of its Passenger business to Joby Aviation, Inc. Joby will pay the initial consideration in stock and may provide up to an additional $35 million based on employee retention and financial performance targets over the next 18 and 12 months, respectively. There is also a potential release of up to $10 million in indemnity holdbacks, payable in cash or stock at Joby’s discretion.
Rebranding Announcement: The company has officially rebranded from Blade Air Mobility, Inc. to Strata Critical Medical, now trading under the ticker symbol SRTA. This change reflects a complete focus on organ logistics and medical services.

Strategic Focus and Growth Plans

Market Positioning: Strata aims to leverage its industry-leading organ transplant logistics platform, emphasizing rapid response times and cost efficiency through an asset-light aircraft network. The company is positioned to expand its services in the medical logistics sector.
Growth Strategy: Co-CEO Will Heyburn highlighted a unique 'one-call' logistics solution that allows Strata to procure various services from third parties, creating multiple growth opportunities through organic growth, strategic partnerships, and acquisitions.

Financial Outlook

2025 Revenue Projections: Strata has updated its financial guidance for 2025, projecting revenues between $160 million and $170 million, alongside a double-digit Adjusted EBITDA.
Cost Management: The company anticipates a reduction in adjusted unallocated corporate expenses and software development costs to approximately $3.5 million per quarter by Q4 2025.

Future Engagements

Investor Day Announcement: Strata plans to hold an investor day in the fall, with further details to be provided in the coming weeks, indicating a commitment to transparency and engagement with stakeholders.

Company Overview

Core Services: Strata Critical Medical specializes in time-critical logistics solutions and medical services for healthcare providers across the U.S., with its subsidiary, Trinity Medical Solutions, leading in the transportation of human organs for transplant.

Forward-Looking Statements

Caution on Predictions: The press release includes forward-looking statements that involve risks and uncertainties, emphasizing that actual results may differ significantly from projections due to various factors, including market conditions and operational challenges.

JOBY

$14.165+Infinity%1D

Analyst Views on JOBY

Wall Street analysts forecast JOBY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JOBY is 15.67 USD with a low forecast of 8.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Analyst Rating

1 Buy

3 Hold

2 Sell

Hold

Current: 14.540

Low

8.00

Averages

15.67

High

22.00

Current: 14.540

Low

8.00

Averages

15.67

High

22.00

Needham

Chris Pierce

Buy

maintain

$22

2025-11-06

Reason

Needham

Chris Pierce

Price Target

$22

AI Analysis

2025-11-06

maintain

Buy

Reason

Needham analyst Chris Pierce keeps a Buy rating and $22 price target on Joby Aviation after its Q3 results and commentary. The company continues to exhibit strong momentum with their S4 aircraft against an improving eVTOL backdrop, increasing confidence in international use cases, and pulling forward potential domestic flight while increasing investor comfort in eventual type certification, the analyst tells investors in a research note.

JPMorgan

Underweight

maintain

$7 -> $8

2025-10-31

Reason

JPMorgan

Price Target

$7 -> $8

2025-10-31

maintain

Underweight

Reason

JPMorgan raised the firm's price target on Joby Aviation to $8 from $7 and keeps an Underweight rating on the shares. The firm updated the company's model.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for JOBY

Unlock Now

H.C. Wainwright

Buy -> Neutral

downgrade

2025-08-07

Reason

H.C. Wainwright

Price Target

2025-08-07

downgrade

Buy -> Neutral

Reason

H.C. Wainwright downgraded Joby Aviation to Neutral from Buy without as price target. The firm cites valuation for the downgrade with the shares up 400% since it initiatied coverage on September 3, 2024. At current valuations, Joby is pricing in multiple near- to-mid-term catalysts related to flight testing, certifications, manufacturing ramp, and commercialization, the analyst tells investors in a research note.

Canaccord

Buy

Hold

downgrade

$12 -> $17

2025-08-07

Reason

Canaccord

Price Target

$12 -> $17

2025-08-07

downgrade

Buy

Hold

Reason

Canaccord downgraded Joby Aviation to Hold from Buy with a price target of $17, up from $12.

About JOBY

Joby Aviation, Inc. is a transportation company developing an all-electric, vertical take-off and landing air taxi. The Company is engaged in designing and testing a piloted all-electric, vertical take-off and landing (eVTOL) aircraft. The Joby eVTOL is designed to transport a pilot and up to four passengers or an expected payload of up to 1,000 pounds at speeds of up to 200 miles per hour (mph). The aircraft is optimized for urban routes, with a target range of up to 100 miles on a single charge. The Company plans to manufacture, own and operate its aircraft itself, building a vertically integrated transportation company that delivers transportation services to customers, including government agencies such as the United States Air Force (USAF) through sales or contracted operations, and to individual end-users through a convenient app-based aerial ridesharing service. It also offers a network of terminals and loyal flyers in markets like New York and in Southern Europe.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.